NasdaqCM:MBRX

Stock Analysis Report

Executive Summary

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates.

Snowflake

Fundamentals

Excellent balance sheet and overvalued.

Share Price & News

How has Moleculin Biotech's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

MBRX

4.6%

US Biotechs

3.4%

US Market


1 Year Return

-19.7%

MBRX

-10.1%

US Biotechs

5.4%

US Market

Return vs Industry: MBRX underperformed the US Biotechs industry which returned -10.1% over the past year.

Return vs Market: MBRX underperformed the US Market which returned 5.4% over the past year.


Shareholder returns

MBRXIndustryMarket
7 Day0%4.6%3.4%
30 Day-14.3%-2.4%-1.0%
90 Day-15.6%-2.1%-0.4%
1 Year-19.7%-19.7%-9.4%-10.1%7.7%5.4%
3 Year-62.1%-62.1%14.9%10.9%46.2%36.8%
5 Yearn/a2.3%-2.7%65.6%47.5%

Price Volatility Vs. Market

How volatile is Moleculin Biotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Moleculin Biotech undervalued compared to its fair value and its price relative to the market?

2.09x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate MBRX's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate MBRX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MBRX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: MBRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate MBRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MBRX is good value based on its PB Ratio (2.1x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Moleculin Biotech forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

34.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MBRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MBRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MBRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if MBRX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if MBRX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if MBRX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Moleculin Biotech performed over the past 5 years?

-39.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: MBRX is unprofitable, and losses have increased over the past 5 years at a rate of -39.7% per year.

Accelerating Growth: Unable to compare MBRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MBRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: MBRX has a negative Return on Equity (-45.65%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: MBRX is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: MBRX is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Moleculin Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: MBRX's short term assets ($20.2M) exceeds its short term liabilities ($9.6M)

Long Term Liabilities: MBRX's short term assets (20.2M) exceeds its long term liabilities (171.0K)


Debt to Equity History and Analysis

Debt Level: MBRX is debt free.

Reducing Debt: MBRX had no debt 5 years ago.


Balance Sheet

Inventory Level: MBRX has a low level of unsold assets or inventory.

Debt Coverage by Assets: MBRX's debt is not covered by short term assets (assets are -7.2785375737711E+17x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MBRX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MBRX has less than a year of cash runway if free cash flow continues to reduce at historical rates of -51.8% each year


Next Steps

Dividend

What is Moleculin Biotech's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate MBRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MBRX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if MBRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MBRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MBRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Moleculin Biotech's salary, the management and board of directors tenure and is there insider trading?

3.2yrs

Average management tenure


CEO

Wally Klemp (59yo)

4.3yrs

Tenure

US$1,345,675

Compensation

Mr. Walter V. Klemp, also known as Wally, founded Moleculin Biotech, Inc. in July 2015 and has been its Chief Executive Officer since July 2015 and President since August 23, 2017. He is a Founder of Solit ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Wally's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Wally's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

3.2yrs

Average Tenure

63yo

Average Age

Experienced Management: MBRX's management team is considered experienced (3.2 years average tenure).


Board Age and Tenure

2.0yrs

Average Tenure

67yo

Average Age

Experienced Board: MBRX's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Louis Ploth (65yo)

    Independent Advisor

    • Tenure: 3.2yrs
    • Compensation: US$118.49k
  • Wally Klemp (59yo)

    Founder

    • Tenure: 4.3yrs
    • Compensation: US$1.35m
  • Jon Foster (55yo)

    Executive VP & CFO

    • Tenure: 3.2yrs
    • Compensation: US$845.69k
  • Don Picker (73yo)

    Chief Scientific Officer

    • Tenure: 2.2yrs
    • Compensation: US$439.41k
  • Rob Shepard (67yo)

    Chief Medical Officer

    • Tenure: 3.3yrs
  • Waldemar Priebe

    Co-Founder and Chairman of Scientific Advisory Board

    • Tenure: 0yrs
  • Sandra Silberman (63yo)

    Chief Medical Officer of New Products

    • Tenure: 1.9yrs
  • Jacqueline Northcut (57yo)

    Consultant

    • Tenure: 2.3yrs
    • Compensation: US$69.23k

Board Members

  • Wally Klemp (59yo)

    Founder

    • Tenure: 4.3yrs
    • Compensation: US$1.35m
  • Michael Cannon (74yo)

    Independent Director

    • Tenure: 3.3yrs
    • Compensation: US$100.70k
  • Jorge Cortes

    Member of Scientific Advisory Board

    • Tenure: 1.8yrs
  • John Waymack (67yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Waldemar Priebe

    Co-Founder and Chairman of Scientific Advisory Board

    • Tenure: 0yrs
  • John Climaco (50yo)

    Lead Independent Director

    • Tenure: 2.3yrs
    • Compensation: US$110.70k
  • Elihu Estey

    Member of Scientific Advisory Board

    • Tenure: 1.8yrs
  • Martin Tallman

    Member of Scientific Advisory Board

    • Tenure: 0.6yrs
  • Robert George (69yo)

    Independent Director

    • Tenure: 3.3yrs
    • Compensation: US$106.95k
  • James Abbruzzese

    Member of Science Advisory Board

    • Tenure: 0.8yrs

Company Information

Moleculin Biotech, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Moleculin Biotech, Inc.
  • Ticker: MBRX
  • Exchange: NasdaqCM
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$46.101m
  • Shares outstanding: 45.20m
  • Website: https://www.moleculin.com

Number of Employees


Location

  • Moleculin Biotech, Inc.
  • 5300 Memorial Drive
  • Suite 950
  • Houston
  • Texas
  • 77007
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MBRXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJun 2016
MOLDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2016

Biography

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin that is in Phase I/II clinical trials for the  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 00:18
End of Day Share Price2019/10/15 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.